ASX:VTI

Stock Analysis Report

Visioneering Technologies

Executive Summary

Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses.


Snowflake Analysis

Limited growth with imperfect balance sheet.


Similar Companies

Share Price & News

How has Visioneering Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VTI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-20.0%

VTI

4.3%

AU Medical Equipment

0.1%

AU Market


1 Year Return

-76.8%

VTI

-1.7%

AU Medical Equipment

-22.8%

AU Market

Return vs Industry: VTI underperformed the Australian Medical Equipment industry which returned -1.7% over the past year.

Return vs Market: VTI underperformed the Australian Market which returned -22.8% over the past year.


Shareholder returns

VTIIndustryMarket
7 Day-20.0%4.3%0.1%
30 Day-55.6%-23.9%-28.8%
90 Day-65.2%-27.1%-30.1%
1 Year-76.8%-76.8%-0.04%-1.7%-19.4%-22.8%
3 Year-96.3%-96.3%17.8%12.4%-9.5%-21.7%
5 Yearn/a57.1%43.7%2.1%-20.8%

Price Volatility Vs. Market

How volatile is Visioneering Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Visioneering Technologies undervalued compared to its fair value and its price relative to the market?

3.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VTI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VTI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VTI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: VTI is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VTI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VTI is overvalued based on its PB Ratio (4x) compared to the AU Medical Equipment industry average (3.2x).


Next Steps

Future Growth

How is Visioneering Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

35.7%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VTI's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if VTI's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VTI's revenue (35.7% per year) is forecast to grow faster than the Australian market (4.2% per year).

High Growth Revenue: VTI's revenue (35.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VTI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Visioneering Technologies performed over the past 5 years?

-18.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VTI is currently unprofitable.

Growing Profit Margin: VTI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VTI is unprofitable, and losses have increased over the past 5 years at a rate of -18.4% per year.

Accelerating Growth: Unable to compare VTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).


Return on Equity

High ROE: VTI has a negative Return on Equity (-1284.83%), as it is currently unprofitable.


Next Steps

Financial Health

How is Visioneering Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: VTI's short term assets ($5.2M) exceed its short term liabilities ($1.8M).

Long Term Liabilities: VTI's short term assets ($5.2M) exceed its long term liabilities ($3.1M).


Debt to Equity History and Analysis

Debt Level: VTI's debt to equity ratio (291.5%) is considered high.

Reducing Debt: Insufficient data to determine if VTI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: VTI has a high level of physical assets or inventory.

Debt Coverage by Assets: VTI's debt is covered by short term assets (assets are 1.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VTI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VTI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -24.8% each year


Next Steps

Dividend

What is Visioneering Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VTI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Stephen Snowdy (49yo)

6.75s

Tenure

Dr. Stephen Snowdy, Ph.D., has been Chief Executive Officer of Visioneering Technologies, Inc. June 2013, its Executive Director since November 25, 2008 and served as its President. Dr. Snowdy is a Princip ...


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Snowdy
CEO & Executive Director6.75yrsno datano data
Richard Griffin
Founder & Medical Adviserno datano datano data
Brian Lane
Chief Financial Officer1.25yrsno datano data
Tony Sommer
Senior Vice President of Sales & Marketing3.5yrsno datano data
Julian Rockett
Company Secretary1.08yrsno datano data
Layna Mendlinger
Executive Director of Marketingno datano datano data
Douglas Benoit
Executive Director of Professional Affairs2.5yrsno datano data

2.5yrs

Average Tenure

Experienced Management: VTI's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stephen Snowdy
CEO & Executive Director6.75yrsno datano data
Christine van Heek
Independent Non-Executive Director11.33yrsno data0.091% $6.8k
David Mazzo
Non-Executive Chairman of the Boardno datano datano data
Zita Peach
Independent Non-Executive Director3.08yrsno data0.023% $1.7k
Jean Franchi
Independent Non-Executive Director2.25yrsno datano data
Tom Dooley
Independent Non-Executive Director2.83yrsno datano data

3.1yrs

Average Tenure

54yo

Average Age

Experienced Board: VTI's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 50.2%.


Top Shareholders

Company Information

Visioneering Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Visioneering Technologies, Inc.
  • Ticker: VTI
  • Exchange: ASX
  • Founded: 2008
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$7.453m
  • Shares outstanding: 465.80m
  • Website: https://www.vtivision.com

Number of Employees


Location

  • Visioneering Technologies, Inc.
  • 10745 Westside Way
  • Suite 200
  • Alpharetta
  • Georgia
  • 30009
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VTIASX (Australian Securities Exchange)Class A Common StockAUAUDNo data
VTIASX (Australian Securities Exchange)YesCDI 1:1AUAUDMar 2017
VTICHIA (Chi-X Australia)YesCDI 1:1AUAUDMar 2017

Biography

Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses. The company offers NaturalVue, a contact lense for adults with presbyopia and children with myopia. It operates in the United States, Australia, New Zealand, Europe, Hong Kong, and Singapore. The company was founded in 2008 and is headquartered in Alpharetta, Georgia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 10:52
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.